Kite part­ner Hi­FiBiO clos­es $67M round for pre­clin­i­cal an­ti­body can­di­dates churned out of sin­gle-cell an­a­lyt­ics plat­form

A fledg­ling biotech with op­er­a­tions span­ning (the Amer­i­can) Cam­bridge, Paris and Shang­hai has just bagged $67 mil­lion to bring its pipeline of can­cer and au­toim­mune dis­ease-fight­ing an­ti­bod­ies in­to the clin­ic.

De­spite its rel­a­tive­ly low pro­file, Hi­FiBiO boasts of part­ner­ships with well-known play­ers, from pi­lot projects with Pfiz­er and J&J in its ear­ly days to more re­cent col­lab­o­ra­tions with Take­da and Gilead’s Kite sub­sidiary.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER